Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

Table 2 Details of the 6 Patients with HBV reactivation

Patients Characteristics				Baseline			At reactivation
Patient	Age (years)	Gender	Cancer type	Anti-tumor therapy	HBV DNA (IU/mL)	Antiviral prophylaxis	Weeks from start of immunotherapy	HBV DNA (IU/mL)	Peak ALT (U/L)	Anti-PD-1/PD-L1 therapy disruption	Antiviral treatment	Time for achieving HBV-DNA undetectable (weeks)	Time for ALT recovery (weeks)
1	48	M	NPC	Camrelizumab	Undetectable	Nil	3	7.81 × 10³	191.4	Delayed	Entecavir	1	2
2	47	M	NPC	Camrelizumab	Undetectable	Nil	16	6.98 × 10⁴	203.0	Delayed	Entecavir	4	4
3	39	M	Melanoma	Pembrolizumab	Undetectable	Nil	28	2.10 × 10³	27.6	No	Nil	5	NA
4	36	M	HCC	Nivolumab	Undetectable	Entecavir	12	1.80 × 10³	298	Discontinued	Entecavir plus tenofovir	1	3
5	45	M	HNSCC	Toripalimab	Undetectable	Nil	35	4.04 × 10⁶	281.2	Delay	Entecavir	3	6
6^a	41	F	Soft Tissue Sarcoma	Nivolumab	Undetectable	Nil	20	6.00 × 10⁷	465.1	NA	Entecavir	8	4

^aHBV reactivation in this patient occurred 6 weeks after immunotherapy was discontinued; other HBV reactivation occurred during anti-PD-1/PD-L1 thearpy
Abbreviations: M male, F female, HBV hepatitis B virus, NPC nasopharyngeal carcinoma, HCC hepatocellular carcinoma, HNSCC head and neck squamous cell cancer, ALT alanine aminotransferase, NA not applicable